Esophageal cancer screening

Revision as of 15:24, 11 December 2017 by Hadeel Maksoud (talk | contribs)
Jump to navigation Jump to search

Esophageal cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Esophageal cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Esophageal cancer screening On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Esophageal cancer screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Esophageal cancer screening

CDC on Esophageal cancer screening

Esophageal cancer screening in the news

Blogs on Esophageal cancer screening

Directions to Hospitals Treating Esophageal cancer

Risk calculators and risk factors for Esophageal cancer screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]

Overview

Screening may be effective in reducing the incidence of esophageal cancer, if treated early at the dysplasia stage with monoclonal antibody therapy. However, no such program is in effect presently.

Screening

  • There is no program in effect to screen for esophageal cancer at present, however the benefits of screening were demonstrated in a high risk population in China that showed a reduction in the incidence of esophageal cancer by 53%.[1]
  • In 1983, a study was carried out in Hishun village, China.
  • Due to different dietary factors, the incidence of esophageal cancer amongst these people was particularly high.
  • 6758 subjects were examined by esophageal exfoliative cytology, 1729 had marked dysplasia and 2411 had mild dysplasia of esophageal epithelium.
  • Those with marked dysplasia were randomly divided into 3 groups and given: antitumor B (Chinese herbs); retinamide (4-Ethoxycarbophenylretinamide) and placebo.
  • The subjects with mild dysplasia were randomly divided into 2 groups for treatment with riboflavin and placebo.
  • They took their respective treatments for 3 years and were then reexamined using cytology.
  • The incidence of esophageal cancer in the antitumor B group was reduced by 53% as compared with that of the placebo group (8.3%).
  • The incidence of esophageal cancer in retinamide and riboflavin groups were reduced by 33.7% and 19% as compared with those of the control groups.
  • These results demonstrated that the secondary prevention of esophageal cancer is effective in the prevention of esophageal cancer.[1]

References

  1. 1.0 1.1 Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP (1988). "[Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus]". Zhonghua Zhong Liu Za Zhi (in Chinese). 10 (3): 161–6. PMID 3219974.


Template:WikiDoc Sources